Beta-Hydroxybutyrate

Beta-hydroxybutyrate (BHB, 3-hydroxybutyrate) is the most abundant circulating ketone body during states of ketosis. Chemically, BHB is a four-carbon beta-hydroxy carboxylic acid; physiologically active D-BHB is produced by hepatic mitochondrial BDH1 from acetoacetate, with the BHB/AcAc ratio in peripheral blood reflecting the hepatic mitochondrial NADH/NAD+ redox state.

Energy substrate function

BHB is an efficient energy substrate. Oxidation of BHB yields approximately 27 ATP per molecule, comparable to glucose on a per-carbon basis and with favorable ATP-per-oxygen ratio in some tissues. In peripheral cells, BHB is dehydrogenated back to acetoacetate by BDH1, then activated by SCOT (succinyl-CoA:3-oxoacid CoA-transferase) using succinyl-CoA to form acetoacetyl-CoA, which is thiolytically cleaved by thiolase to two acetyl-CoA molecules that enter the TCA cycle. The brain, heart, and skeletal muscle are major BHB consumers during ketosis.

Signaling functions

Beyond energy provision, BHB has emerged as a signaling molecule with several characterized actions. BHB is an endogenous inhibitor of class I histone deacetylases (HDAC1, HDAC2, HDAC3) at concentrations achieved in physiological ketosis, altering chromatin accessibility and gene expression (Shimazu et al., Science 2013). BHB activates the G-protein-coupled receptor HCAR2 (GPR109A), which mediates anti-inflammatory and niacin-like effects. BHB inhibits the NLRP3 inflammasome, reducing IL-1 beta production — a mechanism implicated in ketogenic neurological benefits. Direct post-translational modification via lysine beta-hydroxybutyrylation (Kbhb) has been identified as an additional chromatin-level regulatory mechanism.

Measurement

Point-of-care blood ketone meters (Abbott Precision Xtra, Keto-Mojo, Nova Biomedical) measure BHB electrochemically in finger-stick capillary samples with approximately 0.1 mmol/L precision in the 0-8 mmol/L clinical range. Urinary ketone strips detect acetoacetate via a nitroprusside reaction but not BHB, and become misleading as BHB/AcAc ratio rises in established ketosis. Breath acetone analyzers (Ketonix, LEVL) estimate BHB indirectly through exhaled acetone from acetoacetate decarboxylation.

Clinical BHB concentrations

Characteristic ranges by state: non-ketotic postprandial <0.1 mmol/L; overnight fast 0.1-0.3 mmol/L; 24-hour fast 0.5-1.0 mmol/L; ketogenic diet (adapted) 0.5-3.0 mmol/L; prolonged fast (>1 week) 3-6 mmol/L; diabetic ketoacidosis 5-25+ mmol/L (with acidemia). Exogenous ketone ester supplementation can acutely raise BHB to 3-5 mmol/L independent of endogenous ketogenesis.

Research applications

Therapeutic ketosis via elevated BHB has established efficacy in pediatric drug-resistant epilepsy. Investigational applications include: cognitive function in aging (research programs by Cunnane and others); glycemic control in type 2 diabetes; neurodegenerative disease (Alzheimer, Parkinson) with mixed early-phase results; exercise performance with exogenous ketone esters (mixed findings, some evidence of preserved cognition during hypoxic or high-intensity exercise). None of these extensions to epilepsy has achieved regulatory approval status as of 2026.

Safety profile

BHB at nutritional-ketosis concentrations (up to ~5 mmol/L) in healthy or metabolically impaired adults is well tolerated over months to years in controlled studies. Caution applies in type 1 diabetes (risk of progression to DKA) and in specific inborn errors of ketone metabolism.